Atricure Inc. Stock
Atricure Inc. Stock
Atricure Inc. is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
On the other hand, the target price of 42 € is below the current price of 59.5 € for Atricure Inc., so the potential is actually -29.41%.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | - | - | - | - | - | - | - |
| Orasure Tech | -0.980% | 2.642% | -8.182% | -18.548% | -32.215% | -32.306% | -41.827% |
| scPharmaceuticals | -3.170% | 0.943% | -6.550% | -58.039% | -25.565% | -11.203% | - |
| SI-BONE Inc | -3.700% | -2.985% | -7.143% | -39.815% | -31.579% | -51.128% | - |
Comments
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at JPMorgan Chase & Co. from $42.00 to $34.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Needham & Company LLC from $46.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $32.00 price target on the stock.
Show more
Ratings data for ATRC provided by MarketBeat